Q4 Results Highlights: ITC profit surges over 247%, Sun Pharma's margin rises; board recommends dividend
5 min read | Updated on May 23, 2025, 07:36 IST
SUMMARY
Together with the interim dividend of ₹6.50 per ordinary share declared on February 6, 2025, ITC's total dividend for the financial year ended 31st March, 2025, would be ₹14.35 per ordinary share of ₹1 each.
As many as 164 companies will post their earnings number for the fourth quarter of the financial year 2024-25 on Thursday, May 22.
ITC Q4: Board recommends final dividend of ₹7.85 per share
ITC's board of directors recommended a final dividend of ₹7.85 per equity share of ₹1 each, subject to shareholder approval at the ensuing Annual General Meeting.
The dividend, if approved, will be paid between Monday, July 28, 2025 and Thursday, July 31, 2025. Further, it fixed Wednesday, May 28, 2025 as the record date.
Together with the interim dividend of ₹6.50 per ordinary share declared on February 6, 2025, ITC's total dividend for the financial year ended 31st March, 2025 would be ₹14.35 per ordinary share of ₹1 each, the FMCG company said.
May 22, 2025, 17:34 PM
ITC Q4: Standalone net profit rises three folds to ₹19,562 crore
May 22, 2025, 17:21 PM
Sun Pharma Q4: Board recommends dividend
Sun Pharma's board of directors recommended a final dividend of ₹5.50 per equity share of ₹1 each, subject to shareholder approval at the ensuing Annual General Meeting.
It also fixed Monday, July 7, 2025, as the record date for the divided. Further, the dividend, if approved, will be paid on or before Friday, August 8, 2025.
May 22, 2025, 17:27 PM
Sun Pharma Q4: Consolidated net profit down 19% at ₹2,154 crore
May 22, 2025, 17:13 PM
Honasa Conusmer Q4: Consolidated net profit shrink 18% to ₹25 crore
May 22, 2025, 16:55 PM
Deepak Fertilizers Q4: Management commentary
“This year has been challenging yet transformative, marked by strategic actions that boosted growth across all product segments. Our financial performance for FY 2024–25 highlights resilience, innovation, and a strong foundation for future success,” said S.C. Mehta, Chairman and Managing Director of DFPCL.
“Our shift from a commodity focus to a speciality and solutions-led company is well underway. FY 2025–26 is poised to be a pivotal year—one that will prepare us for a major operational leap, with key capacity expansions nearing completion by H2 FY26. These expansions will elevate us as one of the global leaders in Technical Ammonium Nitrate and Building Block Nitric Acid,” Mehta further said.
May 22, 2025, 15:31 PM
Deepak Fertilizers Q4: Dividend recommended at ₹10 per share for FY25
The company’s board has recommended a dividend at the rate of ₹10 per equity share with a face value of ₹10 each for the financial year 2024-2025. The dividend, if declared at the ensuing Annual General Meeting (AGM), will be paid to the shareholders within 30 days of the Annual General Meeting, Deepak Fertilizers said.
"Further, the Register of Members of the Company will remain closed from Wednesday, 3rd September, 2025, to Tuesday, 9th September, 2025 (both days inclusive) for the purpose of payment of dividend and AGM of the Company," it said.
May 22, 2025, 15:27 PM
Deepak Fertilizers Q4: Net profit rises 21% YoY; margin shrinks
Revenue at ₹2,667.4 crore versus ₹2,086.3 crore, UP 27.9%
Net profit at ₹277.9 crore versus ₹230 crore, UP 20.8%
EBITDA at ₹480 crore versus ₹437.9 crore, UP 9.6%
Margin at 18% versus 21%
May 22, 2025, 15:20 PM
Unichem Lab Q4: Consolidated net profit at ₹53 crore
Revenue at ₹587.2 crore versus ₹459.6 crore, UP 27.8% YoY.
Net profit at ₹53 crore profit versus ₹136.7 crore loss.
May 22, 2025, 15:11 PM
Emcure Pharma Q4: Consolidated net profit surges over 64% YoY
Revenue at ₹2,116 crore versus ₹1,771.3 crore, UP 19.5%.
Net profit at ₹189 crore versus ₹115 crore, UP 64.4%.
May 22, 2025, 15:02 PM
Sun Pharma Q4: How have the shares fared
Sun Pharma shares have given subdued returns to investors so far in 2025. The stock is down over 8.5% this year and 6% in May 2025. US trade tariff threats have impacted the Sun Pharma stock performance.
EBITDA margin is expected to improve on the back of higher sales of the Revlimid, gRevlimid, and Taro pharm drug and sustained growth in domestic formulations.
May 22, 2025, 14:46 PM
Sun Pharma Q4 results today
Pharma major, Sun Pharmaceutical Industries, will announce its March quarter results today. The results are expected to be announced after market hours followed by analyst/ investor meeting.
In the December (Q3FY25) quarter, Sun Pharma registered a consolidated net profit of ₹2,913 crore, up 13% YoY, while its revenue from operations stood at ₹13,675 crore, up 10% YoY during the same period. The company reported revenue of ₹11,983 crore in Q4FY24 and net profit of ₹2,659 crore.
May 22, 2025, 14:36 PM
Strides Pharma Q4: Dividend recommendation for Q4
The pharma company's board has recommended a final dividend of ₹4 per equity share of ₹10 each (at the rate of 40%) for the financial year ending March 31, 2025. "Dividends will be paid within 30 days from the date of shareholders’ approval at the ensuing Annual General Meeting (AGM)," Strides Pharma said.
May 22, 2025, 14:04 PM
Strides Pharma Q4: Consolidated net profit quadruples to ₹82.19 crore YoY
Revenue at ₹1,190.39 crore versus ₹1,043.50 crore, UP 14.1%
Net profit at ₹82.19 crore versus ₹18.18 crore, UP 352%
EBITDA at ₹217.86 crore versus ₹204.32 crore, UP 7%
Margin at 18.3% versus 19.6%
May 22, 2025, 13:46 PM
Clean Science Q4: Dividend recommended for FY25
The company's board has recommended a final dividend of ₹4 (400%) per equity share of the face value of ₹1 each for the financial year ending March 31, 2025. "The final dividend is subject to the approval of the members at the ensuing Annual General Meeting, which will be held within the stipulated timeline as per the provisions of the Companies Act, 2013," the firm said.
May 22, 2025, 13:14 PM
Clean Science Q4: Consolidated net profit rises 6% YoY
Revenue at ₹263.6 crore versus ₹227.5 crore, UP 15.8%.
Net profit at ₹74.09 crore versus ₹70.2 crore, UP 5.7%.
EBITDA at ₹105 crore versus ₹95 crore, UP 10.6%.
Margin at 39.8% versus 41.7%
May 22, 2025, 13:00 PM
ITC Q4: Technical view
The technical structure of the ITC remains weak as it trades below its 200-day exponential moving average (EMA) for five months. Additionally, it is facing resistance from the downward sloping trendline connecting its all-time high and January siwng high.
May 22, 2025, 12:53 PM
ITC Q4 preview: Net profit likely to fall
The FMCG major ITC is expected to report mixed earnings, with low single-digit revenue growth and a decline in net profit. Experts believe ITC is likely to post a 1–3% year-on-year (YoY) increase in standalone revenue, reaching ₹16,500–₹16,850 crore. This growth is expected to be driven by higher sales in its FMCG and cigarettes segments.
However, profitability may be under pressure. Net profit is projected to decline 6–8% YoY to ₹4,600–₹4,700 crore, largely due to margin compression from rising raw material costs.
May 22, 2025, 12:44 PM
Q4 results on May 22: Check list
May 22, 2025, 12:27 PM
Q4 earnings updates: Check the list firms to declare March quarter earnings today
As many as 164 companies will post their earnings number for the fourth quarter of the financial year 2024-25 on Thursday, May 22. This includes Container Corporation of India (CONCOR), Emcure Pharmaceuticals, GMR Airports, Honasa Consumers, ITC Ltd, Max Estates, The Ramco Cements, Reliance Home Finance, Sun Pharmaceuticals and Strides Pharma Science.
May 22, 2025, 12:21 PM